Neuraxpharm Sustainability Profile
Neuraxpharm, a leading pharmaceutical company headquartered in Spain, is renowned for its commitment to improving the lives of patients with central nervous system (CNS) disorders. Founded in 1985, the company has established a strong presence across Europe, focusing on the development and distribution of innovative treatments for mental health conditions, including depression and anxiety. With a diverse portfolio of products, Neuraxpharm stands out for its specialised formulations and patient-centric approach. The company has achieved significant milestones, including strategic acquisitions that have expanded its market reach and enhanced its product offerings. As a trusted name in the pharmaceutical industry, Neuraxpharm continues to prioritise research and development, solidifying its position as a key player in the CNS market.
DitchCarbon Score
How does Neuraxpharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Neuraxpharm's score of 37 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Neuraxpharm's reported carbon emissions
In 2025, Neuraxpharm reported total carbon emissions of approximately 917,000 kg CO2e, comprising 66,000 kg CO2e from Scope 2 and 851,000 kg CO2e from Scope 3 emissions. The previous year, 2024, saw emissions of about 578,000 kg CO2e, with 8,000 kg CO2e from Scope 2 and 570,000 kg CO2e from Scope 3. In 2023, emissions were around 454,000 kg CO2e, including 1,000 kg CO2e from Scope 2 and 453,000 kg CO2e from Scope 3. Neuraxpharm's emissions data from 2022 indicates a total of 3,526,000 kg CO2e, with 2,064,000 kg CO2e from Scope 1 and 1,462,000 kg CO2e from Scope 2. The company has not reported any Scope 1 emissions in the years 2023 to 2025. Despite the significant emissions figures, Neuraxpharm has not established specific reduction targets or initiatives, nor have they committed to any climate pledges or SBTi targets. The absence of reduction initiatives suggests a need for enhanced climate action within the organisation. Overall, Neuraxpharm's emissions profile reflects a reliance on Scope 2 and Scope 3 emissions, highlighting the importance of addressing indirect emissions in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000 | 0,000,000 | - | - | - |
| Scope 2 | 446,000 | 000,000 | 0,000,000 | 0,000 | 0,000 | 00,000 |
| Scope 3 | 325,000 | - | - | 000,000 | 000,000 | 000,000 |
How Carbon Intensive is Neuraxpharm's Industry?
How Carbon Intensive is Neuraxpharm's Location?
Neuraxpharm's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Neuraxpharm has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
